UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Therapeutic advances in neurological disorders, 2021-01, Vol.14, p.17562864211012835-17562864211012835

2021

Volltextzugriff (PDF)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

Journal of neurology, 2022-05, Vol.269 (5), p.2286-2292

2022

Volltextzugriff (PDF)

Deciphering the shift from benign to active relapsing-remitting multiple sclerosis: Insights into T regulatory cell dysfunction and apoptosis regulation

Neurobiology of disease, 2024-05, Vol.194, p.106475-106475, Article 106475

2024

Volltextzugriff (PDF)

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients

International journal of infectious diseases, 2022-02, Vol.115, p.208-214

2022

Volltextzugriff (PDF)

Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation

PloS one, 2013-09, Vol.8 (9), p.e73625

2013

Volltextzugriff (PDF)

Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy

PloS one, 2011-09, Vol.6 (9), p.e22849

2011

Volltextzugriff (PDF)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Therapeutic advances in neurological disorders, 2021, Vol.14, p.17562864211020082-17562864211020082

2021

Volltextzugriff (PDF)

Coronavirus 2019 outbreak pathogenesis: Why China and Italy?

European journal of rheumatology, 2020-08, Vol.7 (Suppl 2), p.S99-S101

2020

Volltextzugriff (PDF)

Advances in microbial biofilm prevention on indwelling medical devices with emphasis on usage of acoustic energy

Sensors, 2009-04, Vol.9 (4), p.2538-2554

2009

Volltextzugriff (PDF)

Impaired Expression of Peripheral Blood Apoptotic-Related Gene Transcripts in Acute Multiple Sclerosis Relapse

Annals of the New York Academy of Sciences, 2007-06, Vol.1107 (1), p.155-167

2007

Volltextzugriff (PDF)

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis

Multiple sclerosis journal - experimental, translational and clinical, 2023-01, Vol.9 (1), p.20552173221151127-20552173221151127

2023

Volltextzugriff (PDF)

Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity

Annals of neurology, 2004-03, Vol.55 (3), p.410-417

2004

Volltextzugriff (PDF)

Effective Prevention of Microbial Biofilm Formation on Medical Devices by Low-Energy Surface Acoustic Waves

Antimicrobial Agents and Chemotherapy, 2006-12, Vol.50 (12), p.4144-4152

2006

Volltextzugriff (PDF)

Cytokine prediction of mortality in COVID19 patients

Cytokine (Philadelphia, Pa.), 2020-10, Vol.134, p.155190-155190, Article 155190

2020

Volltextzugriff (PDF)

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

Clinical microbiology and infection, 2021-09, Vol.27 (9), p.1349.e1-1349.e6

2021

Volltextzugriff (PDF)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Journal of neuroimmunology, 2021-12, Vol.361, p.577746-577746, Article 577746

2021

Volltextzugriff (PDF)

Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4

Journal of neuroimmunology, 2022-11, Vol.372, p.577966-577966, Article 577966

2022

Volltextzugriff (PDF)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

Journal of the neurological sciences, 2022-03, Vol.434, p.120155-120155, Article 120155

2022

Volltextzugriff (PDF)

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?

European journal of internal medicine, 2021-12, Vol.94, p.105-107

2021

Volltextzugriff (PDF)

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis

Immunologic research, 2022-12, Vol.70 (6), p.817-828

2022

Volltextzugriff (PDF)

Coronavirus 2019 outbreak pathogenesis: Why China and Italy?

European journal of rheumatology, 2020-08, Vol.7 (S2), p.S99

2020

Volltextzugriff (PDF)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents

Pediatric allergy and immunology, 2022-10, Vol.33 (10), p.e13863-n/a

2022

Volltextzugriff (PDF)

Convalescent Whole Blood Donors Screening Strategies for Providing Efficient and Safe COVID-19 Survivors' Plasma and Other Blood Components

The Israel Medical Association journal, 2021-01, Vol.23 (1), p.7-10

2021

Volltextzugriff (PDF)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

Multiple sclerosis and related disorders, 2023-04, Vol.72, p.104616-104616, Article 104616

2023

Volltextzugriff (PDF)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19 m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

Multiple sclerosis and related disorders, 2023-03

2023

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(72)

Sprache

Englisch
(71)
Hebräisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

Deciphering the shift from benign to active relapsing-remitting multiple sclerosis: Insights into T regulatory cell dysfunction and apoptosis regulation

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients

Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation

Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Coronavirus 2019 outbreak pathogenesis: Why China and Italy?

Advances in microbial biofilm prevention on indwelling medical devices with emphasis on usage of acoustic energy

Impaired Expression of Peripheral Blood Apoptotic-Related Gene Transcripts in Acute Multiple Sclerosis Relapse

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis

Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity

Effective Prevention of Microbial Biofilm Formation on Medical Devices by Low-Energy Surface Acoustic Waves

Cytokine prediction of mortality in COVID19 patients

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis

Coronavirus 2019 outbreak pathogenesis: Why China and Italy?

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents

Convalescent Whole Blood Donors Screening Strategies for Providing Efficient and Safe COVID-19 Survivors' Plasma and Other Blood Components

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

In-depth characterization of long-term humoral and cellular immune responses to COVID-19 m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

Suchergebnisse filtern